Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma
NCT04063683Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Oct 2019
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Henan Cancer Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04063683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04063683.